Trial Profile
A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Tesetaxel (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 29 Jun 2011 This trial is expected to be a 'run-in' for a planned phase III trial of tesetaxel first-line therapy in advanced gastric cancer, according to a Genta media release.
- 29 Jun 2011 Accrual at the first dosing level in phase I has been completed, according to a Genta media release.
- 13 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.